


Altered Vasoconstrictor signaling: Rho-kinase and PKC, new players in an old problem

Christopher J. Wingard, Ph.D.



Department of Physiology
and
The Vascular Biology Center



Medline Search Results mid 1960's - present

■ Penile circ & Vasoconstrictors	36
■ Coronary circ & Vasoconstrictors	197
■ Cerebral circ & Vasoconstrictors	266
■ Systemic circ & vasoconstrictors	250
■ Erection/ED & Vasoconstrictors	57
■ Erection/ED & Nitric oxide	624

Diabetes and ED Statistics

- > 50 % of all men with DM have some form of ED
 - (estimated 8 million US men).
- Onset of ED occurs earlier with DM
 - (usually within 10 years of DM onset).
- A variety of pathological changes are associated with DMED.
 - Psychological function
 - Central and peripheral nerve function
 - Steroid metabolism
 - **Vascular function**

Vascular Changes

- Reduced relaxation to ACH, NO-cGMP, or PGE1-cAMP.
- Impairment of neurogenic NO and cGMP production.
- Direct relaxation by NVDs are usually unaffected.
- Increases in expression of AGE's and iNOS.
- Altered tissue morphology.
- Altered smooth muscle responsiveness to vasoconstrictors.

Altered Vascular Reactivity

■ Impaired Relaxations:


- Involving both endothelial-dependent and independent mechanisms.

■ Elevated Constrictor Activity:

- Increased constrictor tone through alteration in receptor levels/activity.
- Increased action of signaling pathways.

Working Hypothesis


The erectile dysfunction observed in Zucker obese-diabetic animal model is mediated through alteration of vasoconstrictor regulation of cavernosal smooth muscle tone.



Metabolic Syndrome X

- Cluster of metabolic diseases including, insulin resistance, glucose intolerance, obesity, hypertension and hyperlipidemia.
- The Zucker rat (ZDF) is a obese, hypertensive, hyperglycemic rat with a nonsense mutation of the leptin receptor gene, (Recessive trait and displays no leptin receptor expression).


Erectile Response




Wingard *et al.*, *Physiologist*, 46: 237, 2003

Contractile Responses

PE



ET-1



RhoA/Rho-kinase maintained vasoconstriction in diabetic tissues

- Vascular tissues contain RhoA & Rho-kinase.

- **Vascular tissues:**

- Miao et al., Life Science, 71:1175-1185, 2002.*


- Sandu et al., Diabetes, 49:2178-2189, 2000.*

- **Specific for erectile tissues:**


- Chang et al., Int J Impotence Res 15:53-62, 2003.*

- Wingard et al., The Physiologist, 46:237, 2003.*

A



B





Confocal images of rat cavernosal smooth muscle cells

A: Rho-kinase α

B: RhoA


Green (FITC), blue (DAPI)

ROCK Expression in Obese-Diabetic Erectile Tissues




Rho-kinase Inhibition

HA-1077



Y-27632



PKC maintained vasoconstriction in diabetic tissues

■ Vascular/urogenital tissues:

Igarashi et al., J. Clin Invest 103:185-195, 1999.

Qu X, et al., J of Endocrin, 162:207-214, 1999.

Sandu et al, Diabetes, 49:2178-2189, 2000.

Miao et al, Life Science, 71:1175-1185, 2002.


■ Specific for erectile tissues:

Nangle et al., Eur J Pharmacol, 475:99-106, 2003.



Wingard et al , The Physiologist, 46: 237, 2003.

Husain et al., IJIR, in press, 2003.

PKC Expression in Obese-Diabetic Erectile Tissues




Inhibition of Classical PKCs



PKC RhoA/Rho-kinase Interactions to Regulate Contractile Effects

- Mutual stimulation of Ca²⁺-sensitization.
 - Chang, et al., *Mol Cell. Biol.*, 18:49-86-4993, 1998.
 - Strassheim, et al., *J Biol. Chem.*, 274:18675-18685, 1999.
 - Thieme et al., *Inv. Opth and Visual Sci.*, 41:4240-4246, 2000.
 - Slater et al., *Biochem* 40:4437-4445, 2001
- Parallel activation of Ca²⁺-sensitization processes.
 - Akopov et al., *Am J Physiol.*, 275: H930-H939, 1998.
 - Fu et al., *FEBS Lett.*, 440:183-187, 1998.
 - Eto et al., *J Biol Chem.*, 276:29072-29078, 2001.
 - Bitar, et al., *J App Physiol.*, 92:41-49, 2002.

RhoA, ROCK α , and PKC α Association



Conclusions

- Voltage-dependent erectile response in obese-diabetics are lower than lean age-matched animals.
- The constrictors (PE and ET-1) responses of isolated CC from the obese-diabetic animals showed augmented forces.
- Relaxations via ROCK inhibition (HA-1077 or Y-27632) or NO donation (SNP) were not different between lean and obese-diabetic tissues.
- CC tissues from obese-diabetics showed elevated expression of RhoA, ROCK α and β , and PKC α , δ , and ϵ .
- Agonist stimulation elevated the amount of PKC α and ROCK α co-immunoprecipitated with RhoA.

Continuing Questions

■ Signaling pathway interactions

- Do the vasoconstrictors work through a single Ca^{2+} -sensitization process?
- What are the interactions of the NO/cGMP signaling with Rho/ROCK pathway?

■ Longitudinal changes in diabetic state

- What are the consequences of long term glycemic control?
- What are the anatomical alterations contribution to the reactivity?

■ Clinical consequences

- What is the impact of targeting specific elements of the signaling process for treatment of ED?
- What is the relationship of multi-factorial disorders to erectile function?

Summary and Directions

- Signaling mechanism for the vasoconstrictor pathways in erectile tissue exhibit a complexity similar to that described for other vascular beds.
- Rho/Rock and PKCs appear to play roles in modulation of cavernosal smooth muscle contraction and erection of diabetics.
- Therapeutic targeting of these signaling pathways might be useful in alleviating erectile dysfunction associated with diabetes.

